A New Self-Reported Assessment Measure for COVID-19 Anxiety Scale (CDAS) in Iran: A Web-Based Study
Background: Given the epidemic of Corona disease and its associated anxiety, it is necessary to develop a tool to measure anxiety. This study was conducted to instruct Corona Disease Anxiety Scale (CDAS) to measure the level of anxiety, during the prevalence of the COVID-19 in Iran.
Methods: The present study was considered as applied research in terms of purpose and descriptive-correlational research in terms of methodological. 318 individuals (aged from 18 to 60 years old) completed the Corona Disease Anxiety Scale (CDAS) and the General Health Questionnaire (GHQ) online
Results: Corona Disease Anxiety Scale had a good internal consistency (α=0.91) and good convergent validity, correlating with the GHQ-28 (r=0.49, P>0.01). Exploratory analysis revealed psychological and physical factors. These 2 factor account for 51% of the total variance and 9 items were loaded on every factor.
Conclusion: This scale is reliable and valid scale for measuring Corona anxiety in non-clinical Iranian population.
2. Centers for Disease Control and Prevention (2020). Coronavirus Disease. Available from: http://www.cdc.gov/coronavirus/index.html
3. Fischhoff B (2020). The unknown is more likely to spark fear than the known, Cen-ters for Disease Control and Prevention (CDC). Available from: www.cdc.gov
4. Grohol M (2020). Coronavirus Anxiety: 4 Ways to Cope with Fear, Centers for Disease Control and Prevention (CDC). Available from: www.cdc.gov
5. Stein M (1989). Stress, depression and the immune system. J Clin Psychiatry, 50: 35-40.
6. Eisner M D, Blanc P D, Yelin E H et al (2010). Influence of anxiety on health outcomes in COPD. Thorax, 65(3): 229-234.
7. 7. Goldberg D, Williams P (1988). A user’s guide to the General Health Questionnaire. Windsor, UK: NFER-Nelson.
8. Taghavi MR (2008). The normalization of General Health Questionnaire for Shiraz university student (GHQ-28). CPAP, 1(28):1- 12.
9. Guyatt G H, Berman L B, Townsend M, Pugsley S O, Chambers L W (1987). A measure of quality of life for clinical trials in chronic lung disease. Thorax, 42(10): 773-778.
10. Dong X Y, Wang L, Tao Y X et al (2017). Psychometric properties of the Anxiety Inventory for Respiratory Disease in pa-tients with COPD in China. Int J Chron Obstruct Pulmon Dis, 12: 49-58.
11. Willgoss T G, Goldbart J, Fatoye F, Yohan-nes A M (2013). The development and validation of the anxiety inventory for respiratory disease. Chest, 144(5): 1587-1596.
12. Domingo-Salvany A, Lamarca R, Ferrer M et al (2002). Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166(5): 680-685.
13. Lareau S C, Blackstock F C (2018). Func-tional status measures for the COPD pa-tient: A practical categorization. Chron Respir Dis, doi: 10.1177/1479973118816464.
14. Ninot G, Soyez F, Préfaut C (2013). A short questionnaire for the assessment of quali-ty of life in patients with chronic obstruc-tive pulmonary disease: psychometric properties of VQ11. Health Qual Life Out-comes, 11(1): 179.